FDA response to Novo supplier eliminates some Wegovy supply concerns
The US Food and Drug Administration will not be shutting down Catalent’s production, which had helped establish Novo Nordisk’s supply of obesity drug Wegovy, while it regains compliance.
by marketwire, translated by daniel pedersen
A response by the US Food and Drug Administration (FDA) to Novo Nordisk’s Belgian subsupplier, Catalent, bodes well for plans to make all dose strengths of obesity drug Wegovy available by year-end, Danish business daily Børsen reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk supplier gets another FDA warning
For subscribers
